Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s presentation of its third-quarter financial results and latest outlook for 2024 as a whole. 5 November 2024
Related News
Insights
Company Spotlight
A clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with diseases of the eye, salivary gland and central nervous system.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
The month of July celebrated World Sjögren's Day, dedicated to Sjögren's syndrome (SS) – a condition affecting between 0.5% and 1% of the population.1 30 July 2024
Pharmaceutical
Shares in North Carolina, USA-based vTv Therapeutics (Nasdaq: VTVT) have fallen over a quarter after the firm announced a clinical hold on its diabetes program. 30 July 2024
Biotechnology
GSK and USA-based biotech incubator Flagship Pioneering have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines. 29 July 2024
Pharmaceutical
On the research front, China’s BioCity Biopharma recently released positive trial results for its ETA antagonist SC0062 in the treatment of chronic kidney disease. Also of note, US pharma giant Merck & Co announced new Phase II/III data demonstrating the promise of its clesrovimab in preventing respiratory syncytial virus (RSV)in infants. Last week saw a batch of second-quarter 2024 financial results reports, including from two of Europe’s largest pharma companies – the UK’s AstraZeneca and France’s Sanofi. 28 July 2024
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
Biotechnology
Belgian clinical-stage G-protein coupled receptor (GPCR) company Confo Therapeutics today announced the closing of a 60 million euros Series B financing 26 July 2024
Pharmaceutical
US drugmaker AbbVie was trading 3% higher early afternoon Thursday. 25 July 2024
Biotechnology
The appointment of Dr Sicard comes at a time when the company has selected its lead candidate, DGX-01, a first-in-class recombinant protein that aims to replicate insulin-producing beta cells in t 25 July 2024
Biotechnology
Californian drugmaker BioMarin Pharmaceutical (Nasdaq: BMRN) has announced that the US Food and Drug Administration has approved a label expansion for Brineura (cerliponase alfa). 25 July 2024
Pharmaceutical
French drugmaker Sanofi was trading more than 3% higher during Thursday afternoon’s trading in Paris. 25 July 2024
Latest In Brief for Vertex Pharmaceuticals
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
29 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze